Company intelligence / Profile preview

Pharma PASS, Inc.

California, United Statespharmapass.ca ↗

Ownership: Private
Development stage: Commercial

Overview

Pharma PASS, Inc. develops pharmaceutical products and has entered into licensing agreements for at least two drug candidates (BVF‑068 and BVF‑247) with Biovail Corporation. These products are intended to address safety issues inherent in currently marketed formulations. The company appears active as of early 2025 but detailed clinical results are not publicly available.

Modalities: Likely small molecules based on typical pharma partnerships and drug development context
Industry: Biotech

Drug pipeline

4 assets

bupropion

Commercial

Indications: Depression, Seasonal Affective Disorder

3 more assets in the full pipeline.

Request access →

Partnerships

Biovail Corporation – worldwide rights deal for two products including upfront/milestone payments and royalties.

Beyond the preview

Go deeper on Pharma PASS, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pharma PASS, Inc..

Explore the full profile